BACKGROUND: Multiple system atrophy (MSA) is a neurodegenerative disorder characterised by autonomic dysfunction with parkinsonism (MSAp) or cerebellar (MSAc) symptoms. At autopsy, α-synuclein inclusions in glial cells of the brain are needed to confirm a definite diagnosis. We determined the 10 year incidence of MSA, point prevalence and survival in a well defined population with a high number of neurologists. METHODS: Cases were identified from the only neurology department and all practising neurologists in Iceland, over a 10 year period. The diagnosis of MSA was in accordance with the Second Consensus Criteria of MSA. FINDINGS: 19 incidence cases were diagnosed with MSA (11 women, eight men) during the study period, giving an average annual incidence of 0.7:100 000 (95% CI 0.4 to 1.1). Ten cases were alive on the prevalence day, giving a point prevalence of 3.4:100 000 (95% CI 1.6 to 6.3). 16 of the cases had probable and three possible MSA; 16 had MSAp and three had MSAc. Mean age at symptom onset was 65 years and mean age at diagnosis was 68 years. Patients were followed for an average of 31 months, and 15 died during the follow-up period. Survival from symptom onset was mean 5.7 years. The 1 and 5 year survival rates from diagnosis were 74% and 28%, respectively. INTERPRETATION: We reported on the incidence of MSA (both MSAp and MSAc) in a nationwide study where a definite diagnosis of MSA was confirmed in four out of five patients autopsied. We found survival to be shorter than reported in other studies.
BACKGROUND:Multiple system atrophy (MSA) is a neurodegenerative disorder characterised by autonomic dysfunction with parkinsonism (MSAp) or cerebellar (MSAc) symptoms. At autopsy, α-synuclein inclusions in glial cells of the brain are needed to confirm a definite diagnosis. We determined the 10 year incidence of MSA, point prevalence and survival in a well defined population with a high number of neurologists. METHODS: Cases were identified from the only neurology department and all practising neurologists in Iceland, over a 10 year period. The diagnosis of MSA was in accordance with the Second Consensus Criteria of MSA. FINDINGS: 19 incidence cases were diagnosed with MSA (11 women, eight men) during the study period, giving an average annual incidence of 0.7:100 000 (95% CI 0.4 to 1.1). Ten cases were alive on the prevalence day, giving a point prevalence of 3.4:100 000 (95% CI 1.6 to 6.3). 16 of the cases had probable and three possible MSA; 16 had MSAp and three had MSAc. Mean age at symptom onset was 65 years and mean age at diagnosis was 68 years. Patients were followed for an average of 31 months, and 15 died during the follow-up period. Survival from symptom onset was mean 5.7 years. The 1 and 5 year survival rates from diagnosis were 74% and 28%, respectively. INTERPRETATION: We reported on the incidence of MSA (both MSAp and MSAc) in a nationwide study where a definite diagnosis of MSA was confirmed in four out of five patients autopsied. We found survival to be shorter than reported in other studies.
Authors: Elizabeth A Coon; Walter Rocca; Christopher S Melson; J Eric Ahlskog; Joseph Y Matsumoto; Philip A Low; Wolfgang Singer Journal: Parkinsonism Relat Disord Date: 2019-09-13 Impact factor: 4.891
Authors: Ryan R Walsh; Florian Krismer; Wendy R Galpern; Gregor K Wenning; Phillip A Low; Glenda Halliday; Walter J Koroshetz; Janice Holton; Niall P Quinn; Olivier Rascol; Leslie M Shaw; David Eidelberg; Pam Bower; Jeffrey L Cummings; Victor Abler; Judy Biedenharn; Gal Bitan; David J Brooks; Patrik Brundin; Hubert Fernandez; Philip Fortier; Roy Freeman; Thomas Gasser; Art Hewitt; Günter U Höglinger; Matt J Huentelman; Poul H Jensen; Andreas Jeromin; Un Jung Kang; Horacio Kaufmann; Lawrence Kellerman; Vikram Khurana; Thomas Klockgether; Woojin Scott Kim; Carol Langer; Peter LeWitt; Eliezer Masliah; Wassilios Meissner; Ronald Melki; Susanne Ostrowitzki; Steven Piantadosi; Werner Poewe; David Robertson; Cyndi Roemer; Dale Schenk; Michael Schlossmacher; Jeremy D Schmahmann; Klaus Seppi; Lily Shih; Andrew Siderowf; Glenn T Stebbins; Nadia Stefanova; Shoji Tsuji; Sharon Sutton; Jing Zhang Journal: Neurology Date: 2017-12-13 Impact factor: 9.910
Authors: Anna I Wernick; Ronald L Walton; Alexandra I Soto-Beasley; Shunsuke Koga; Michael G Heckman; Rebecca R Valentino; Lukasz M Milanowski; Dorota Hoffman-Zacharska; Dariusz Koziorowski; Anhar Hassan; Ryan J Uitti; William P Cheshire; Wolfgang Singer; Zbigniew K Wszolek; Dennis W Dickson; Phillip A Low; Owen A Ross Journal: Clin Auton Res Date: 2021-01-27 Impact factor: 5.625
Authors: Jesús de Pedro-Cuesta; Pablo Martínez-Martín; Alberto Rábano; María Ruiz-Tovar; Enrique Alcalde-Cabero; Miguel Calero Journal: Front Aging Neurosci Date: 2016-06-13 Impact factor: 5.750